## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL					
MB Number: 3235-028					
stimated average burden					
ours per response	0.5				

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	es)														
Name and Address of Reporting Person * Cheong Kwang Soo			2. Issuer Name and Ticker or Trading Symbol REXAHN PHARMACEUTICALS, INC. [RXHN]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  _X_Director Officer (give title below) Other (specify below)					
(Last) (First) (Middle)			3. Date of Earliest Transaction (Month/Day/Year) 06/11/2007						X							
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)							_X_ F	6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person					
ROCKVILLE, MD 20850 (City) (State) (Zip)											Form filed by More than One Reporting Person					
		(5.5.5)		Table I - Non-Derivative Securities Acqui												
1.Title of Security (Instr. 3)  2. Transaction Date (Month/Day/Year		Execution Date, if any (Month/Day/Year)		Code (Inst	e r. 8)	(A) o	r Disposed of 3, 4 and 5)  (A) or unt (D)	(D) Owner Trans	Owned Following Reported Transaction(s) (Instr. 3 and 4)		d C	Ownership of Form: B	eneficial wnership			
Reminder:	Report on a	separate line for eac		Derivat	ive S	Securitie	s Ac	Perso in this displa quired, Disp	ns w form	ho respond n are not rec currently va of, or Benefic	quired to alid OMB cially Own	respond control r	unless the		ned SEC 14	74 (9-02)
1. Title of	2	3. Transaction	3A. Deemed	( <i>e.g.</i> , pu	ts, c	5. Numb		6. Date Exe			7. Title an	d	8 Price of	9. Number o	f 10.	11. Nature
Derivative Security	Conversion		Execution Date, if	Transaction of Code Derivative		ve es d d of	Expiration Date (Month/Day/Year)			Amount of Underlying Securities (Instr. 3 and 4)		Derivative Security (Instr. 5)	Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Ownership Form of Derivative Security: Direct (D) or Indirect	of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable		Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$ 1.2							05/01/200	7(1)	05/01/2016	Common Stock	20,000		20,000	D	
Stock Option (Right to Buy)	\$ 1.4	06/11/2007		A		20,000		06/11/200	8(1)	06/11/2017	Common Stock	20,000	\$ 0	20,000	D	

#### **Reporting Owners**

Donostino Ossar Norma / Addisor	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Cheong Kwang Soo C/O REXAHN PHARMACEUTICALS, INC. 9620 MEDICAL CENTER DRIVE ROCKVILLE, MD 20850	X					

### **Signatures**

/s/ Tae Heum Jeong, as attorney-in-fact for Kwang Soo Cheong	06/13/2007
**Signature of Reporting Person	Date

#### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Options fully vest on the first anniversary of the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.